D1 receptor agonist improves sleep-wake parameters in experimental parkinsonism.
Neurobiology of Disease. 2014-03-01; 63: 20-24
DOI: 10.1016/j.nbd.2013.10.029
Read on PubMed
1. Neurobiol Dis. 2014 Mar;63:20-4. doi: 10.1016/j.nbd.2013.10.029. Epub 2013 Nov 6.
D1 receptor agonist improves sleep-wake parameters in experimental parkinsonism.
Hyacinthe C(1), Barraud Q(2), Tison F(3), Bezard E(4), Ghorayeb I(5).
Author information:
(1)Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293,
Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293,
Bordeaux, France. Electronic address: .
(2)Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293,
Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293,
Bordeaux, France. Electronic address: .
(3)Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293,
Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293,
Bordeaux, France; Service de Neurologie, CHU de Bordeaux Haut-Lévêque, Pessac,
France. Electronic address: .
(4)Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293,
Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293,
Bordeaux, France; Institute of Laboratory Animal Sciences, China Academy of
Medical Sciences, Beijing, China. Electronic address:
.
(5)Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293,
Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293,
Bordeaux, France; Département de Neurophysiologie Clinique, CHU de Bordeaux
Pellegrin, Bordeaux, France. Electronic address: .
Both excessive daytime sleepiness (EDS) and rapid eye movement (REM) sleep
deregulation are part of Parkinson’s disease (PD) non-motor symptoms and may
complicate dopamine replacement therapy. We report here that dopamine agonists
act differentially on sleep architecture in the
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine macaque monkey. Continuous sleep and
wake electroencephalographic monitoring revealed no effect of the selective
dopamine D2 receptor agonist quinpirole on EDS, whereas the selective dopamine D1
receptor agonist SKF38393 efficiently alleviated EDS and restored REM sleep to
baseline values. The present results question the relevance of abandoning D1
receptor agonist treatment in PD as it might actually improve sleep-related
disorders.
Copyright © 2013 Elsevier Inc. All rights reserved.
DOI: 10.1016/j.nbd.2013.10.029
PMID: 24211719 [Indexed for MEDLINE]